By demonstrating the potential of both ADT-007 and the 3D BEST model, we lay the groundwork for future investigations that could ultimately lead to more effective and personalized treatment strategies for patients with KRAS-mutant CRC and other RAS-driven cancers. Here, KRAS is linked to cancer.